# US 2020/0390703 A1 · Porous silica material for use as a pharmaceutical or dietary active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390703 A1
- Document ID: US20200390703A1
- Status: Published application
- Kind: A1
- Application number: 16/913,533
- Filed: 2020-06-26
- Published: 2020-12-17
- Earliest claimed: 2012-11-06
- Assignees: Sigrid Therapeutics AB
- Applicants: Sigrid Therapeutics AB
- Inventors: Robert Csikasz; Tore Bengtsson; Natalia Kupferschmidt; Alfonso E. Garcia-Bennett
- Web page: https://patentgrep.com/patent/US20200390703A1

## CPC

- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A23L 29/015: {Inorganic compounds}
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/20: Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/12: Antihypertensives
- C01B 33/12: Silica; Hydrates thereof, e.g. lepidoic silicic acid
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C01P 2006/12: Surface area
- C01P 2006/14: Pore volume
- C01P 2006/17: Pore diameter distribution
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of the prophylaxis or treatment of: metabolic syndrome, type 2 diabetes, insulin resistance, or hyperglycemia in a human or animal in need thereof, comprising administering to the human or animal an effective amount of a porous silica material having pores in the mesoscale range of 2-50 nm, wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

### Claim 20

A method of lowering glucose levels in the blood in a human or animal in need thereof, comprising administering to the human or animal an effective amount of a porous silica material having pores in the mesoscale range of 2-50 nm, wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.

### Claim 21 (depends on 19)

The method of claim 19, wherein the porous silica material is the sole active ingredient being administered to the human or animal for the prophylaxis or treatment of: metabolic syndrome, type 2 diabetes, insulin resistance or hyperglycemia.

### Claim 22 (depends on 19)

The method of claim 19, wherein the prophylaxis or treatment of: metabolic syndrome, type 2 diabetes, insulin resistance, or hyperglycemia in a human or animal is achieved by reduction of adipose tissue in the human or animal.

### Claim 23 (depends on 19)

The method of claim 19, wherein the porous silica material is orally administered.

### Claim 24 (depends on 19)

The method of claim 19, wherein the human or animal is obese.

### Claim 25 (depends on 19)

The method of claim 19, wherein the average pore size is in the range of 7 to 15 nm.

### Claim 26 (depends on 19)

The method of claim 19, wherein the average pore size is in the range of 10 to 12 nm.

### Claim 27 (depends on 19)

The method of claim 19, wherein the BET (Brunauer-Emmett-Teller theory) surface area is between 300 and 1300 m2/g

### Claim 28 (depends on 27)

The method of claim 27, wherein the BET surface area is between 500 and 900 m2/g.

### Claim 29 (depends on 19)

The method of claim 19, wherein the pore volume measured by nitrogen adsorption is in the range of 0.3 to 1.7 cm3/g.

### Claim 30 (depends on 19)

The method of claim 19, wherein the porous silica material additionally has a hierarchical porous structure containing both pores in the range of 2 to 50 nm and pores larger than 50 nm.

### Claim 31 (depends on 19)

The method of claim 19, wherein the porous silica material has a minimum particle size distribution of 300 nm.

### Claim 32 (depends on 20)

The method of claim 20, wherein, wherein the porous silica material is the sole active ingredient being administered to the human or animal for lowering glucose levels in the blood.

### Claim 33 (depends on 20)

The method of claim 20, wherein the lowering glucose levels in the blood in a human or animal is achieved by reduction of adipose tissue in the human or animal.

### Claim 34 (depends on 20)

The method of claim 20, wherein the porous silica material is orally administered.

### Claim 35 (depends on 20)

The method of claim 20, wherein the human or animal is obese.

### Claim 36 (depends on 20)

The method of claim 20, wherein the average pore size is in the range of 7 to 15 nm.

### Claim 37 (depends on 20)

The method of claim 20, wherein the average pore size is in the range of 10 to 12 nm.

### Claim 38 (depends on 20)

The method of claim 20, wherein the BET (Brunauer-Emmett-Teller theory) surface area is between 300 and 1300 m2/g.

### Claim 39 (depends on 38)

The method of claim 38, wherein the BET surface area is between 500 and 900 m2/g.

### Claim 40 (depends on 20)

The method of claim 20, wherein the pore volume measured by nitrogen adsorption is in the range of 0.3 to 1.7 cm3/g.

### Claim 41 (depends on 20)

The method of claim 20, wherein the porous silica material additionally has a hierarchical porous structure containing both pores in the range of 2 to 50 nm and pores larger than 50 nm.

### Claim 42 (depends on 20)

The method of claim 20, wherein the porous silica material has a minimum particle size distribution of 300 nm.
